Detection of cholesterol ozonation products

A detectable derivative of a cholesterol ozonation product, comprising a bisulfite adduct, an imine, an oxime, a hydrazone, a dansyl hydrazone, a semicarbazone, or a Tollins test product, wherein the ozonation product of cholesterol is generated within an atherosclerotic plaque.

A hydrazone derivative of an ozonation product of cholesterol, wherein the ozonation product of cholesterol is generated within an atherosclerotic plaque.

A hapten having formula 13a or 13b:

• wherein the hapten can be used to generate antibodies that can react with a ozonation or hydrazone product of cholesterol.

A hapten having formula 14a or 14b:

• wherein the hapten can be used to generate antibodies that can react with a ozonation or hydrazone product of cholesterol.

A hapten having formula 3c:

• wherein the hapten can be used to generate antibodies that can react with a ozonation or hydrazone product of cholesterol.

A hapten having formula 15a:

• wherein the hapten can be used to generate antibodies that can react with a ozonation or hydrazone product of cholesterol.

An isolated antibody that can bind to an ozonation product of cholesterol.

A mono clonal antibody that can bind to an ozonation product of cholesterol.

An isolated antibody that can bind to a hydrazone derivative of an ozonation product of cholesterol.

An isolated antibody, wherein the isolated antibody is a derived from hybridoma KA1-11C5:6 or KA1-7A6:6 having ATCC Accession No. PTA-5427 or PTA-5428.

An isolated antibody, wherein the isolated antibody is a derived from hybridoma KA2-8F6:4 or KA2-1E9:4, having ATCC Accession No. PTA-5429 and PTA-5430.

A method for detecting atherosclerosis in a patient comprising:

• detecting whether an ozonation product of cholesterol is present in the test sample obtained from a patient.

A method for detecting whether an ozonation product of cholesterol is released by an atherosclerotic plaque in a patient comprising:

• detecting whether an ozonation product of cholesterol is present in a test sample obtained from a patient, wherein the ozonation product is a compound comprising formula 5a:

A method for detecting atherosclerosis in a patient comprising:

• adding 2,4-dinitrophenylhydrazine to a test sample from the patient and detecting whether a hydrazone derivative of an ozonation product of cholesterol is present in the test sample.

A method for detecting atherosclerosis in a patient comprising:

• adding dansyl hydrazine to a test sample from the patient and detecting whether a dansyl hydrazone derivative of an ozonation product of cholesterol is present in the test sample.

A method for detecting whether cholesterol ozonolysis products are present in a test sample comprising contacting macrophages with the test sample and determining whether lipid uptake by macrophages is increased.

A method for detecting atherosclerosis in a patient comprising contacting macrophages with a test sample from the patient and determining whether lipid uptake by macrophages is increased.

A method for detecting cholesterol ozonolysis products in a test sample comprising contacting low density lipoproteins with the test sample and observing whether the secondary structure of the low density lipoproteins changes.

A method for detecting atherosclerosis in a patient comprising contacting low density lipoproteins with a test sample obtained from the patient and observing whether the secondary structure of the low density lipoproteins changes.

A method for detecting cholesterol ozonolysis products in a test sample comprising contacting apoprotein B100 with the test sample and observing whether the secondary structure of the apoprotein B100 changes.

A method for detecting atherosclerosis in a patient comprising contacting apoprotein B100 with a test sample obtained from the patient and observing whether the secondary structure of the apoprotein B100 changes.